Why IP Incentives Matter for Life Sciences Innovation – In Europe and Beyond

Posted by:

Why IP incentives matter for life sciences innovation – In Europe and Beyond

Pugatch Consilium is today releasing a new report – A Critical Incentive – Not a Barrier! How IP incentives spur biopharmaceutical innovation and the creation of new health technologies.

This report examines the importance of IP based incentives to biopharmaceutical innovation and the development of new medicines and medical technologies.

This analysis could not be more timely. In Europe, for example, the EU Commission is seriously considering ways to ...

Continue Reading →
Page 2 of 2 12